Please assess the completion status of the following clinical trial:

Trial Title: Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Not currently participating in a drug or medical device clinical trial~* Male or female over the age of 18~* DSM - IV Diagnosis of major depression~* Positive family history of bipolar disorder or completed suicide~Exclusion Criteria:~* Not able to give informed consent~* Pregnant or breast-feeding~* Current additional psychiatric diagnoses including Panic Disorder, Post -Traumatic Stress Disorder (PTSD) or Psychosis~* History of mania or hypomania~* Active substance abuse or dependence in the last 6 months~* Current depressive episode less than 4 weeks or greater than 12 months in duration~* Current or prior adequate trial of lithium or paroxetine~* Current use of other medications such as antidepressants for the treatment of depression~* Clinically significant medical illness, in particular kidney problems

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lithium group (Type: EXPERIMENTAL): Start at 600 mg po hs. Dose titrated up to a serum level of between 0.6 and 1.1 mmol/l.
- paroxetine group (Type: ACTIVE_COMPARATOR): Start dose at 20 mg po od. If no clinical improvement(\<20% reduction in MADRS score) by week 4 dose to be increased to 40 mg po od.

Based on this trial design, predict the completion outcome and termination type (if applicable).